ArticleBritish journal of cancer2025

Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.

Keun-Wook Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.